KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Consensus Recommendation of “Hold” by Analysts

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) have been assigned an average rating of “Hold” from the nine research firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $33.25.

KALV has been the topic of several research analyst reports. Wall Street Zen upgraded shares of KalVista Pharmaceuticals to a “hold” rating in a research report on Saturday, June 13th. JonesTrading cut KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 30th. Citizens Jmp downgraded KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Stifel Nicolaus increased their target price on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. Finally, HC Wainwright cut KalVista Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the company from $37.00 to $27.00 in a research note on Friday, May 1st.

Insider Transactions at KalVista Pharmaceuticals

In other news, insider Paul K. Audhya sold 2,239 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $26.78, for a total transaction of $59,960.42. Following the sale, the insider owned 150,260 shares in the company, valued at approximately $4,023,962.80. The trade was a 1.47% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Brian Piekos sold 1,489 shares of the company’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $26.78, for a total transaction of $39,875.42. Following the completion of the sale, the chief financial officer directly owned 21,661 shares in the company, valued at $580,081.58. This represents a 6.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 39,971 shares of company stock valued at $965,493 in the last three months. Company insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of KALV. Seven Fleet Capital Management LP lifted its position in KalVista Pharmaceuticals by 165.4% during the 1st quarter. Seven Fleet Capital Management LP now owns 128,487 shares of the specialty pharmaceutical company’s stock valued at $2,586,000 after acquiring an additional 80,075 shares during the period. Parallel Advisors LLC grew its holdings in KalVista Pharmaceuticals by 45.8% in the first quarter. Parallel Advisors LLC now owns 1,876 shares of the specialty pharmaceutical company’s stock worth $38,000 after purchasing an additional 589 shares during the period. Optiver Holding B.V. increased its stake in shares of KalVista Pharmaceuticals by 2,981.2% during the first quarter. Optiver Holding B.V. now owns 4,591 shares of the specialty pharmaceutical company’s stock valued at $92,000 after purchasing an additional 4,442 shares in the last quarter. Bank of America Corp DE increased its stake in shares of KalVista Pharmaceuticals by 42.5% during the first quarter. Bank of America Corp DE now owns 555,628 shares of the specialty pharmaceutical company’s stock valued at $11,185,000 after purchasing an additional 165,815 shares in the last quarter. Finally, Royal Bank of Canada increased its stake in shares of KalVista Pharmaceuticals by 137.0% during the first quarter. Royal Bank of Canada now owns 2,917 shares of the specialty pharmaceutical company’s stock valued at $59,000 after purchasing an additional 1,686 shares in the last quarter.

KalVista Pharmaceuticals Price Performance

Shares of KalVista Pharmaceuticals stock opened at $27.00 on Friday. The company has a current ratio of 5.17, a quick ratio of 5.10 and a debt-to-equity ratio of 8.18. The company’s fifty day simple moving average is $26.89 and its two-hundred day simple moving average is $20.39. The company has a market cap of $1.44 billion, a P/E ratio of -7.80 and a beta of -0.12. KalVista Pharmaceuticals has a 12-month low of $9.83 and a 12-month high of $27.00.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings data on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The business had revenue of $40.86 million for the quarter, compared to analyst estimates of $39.03 million. Research analysts anticipate that KalVista Pharmaceuticals will post -1.19 EPS for the current year.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.